- Young Americans are increasingly using suffocation and hanging to commit suicide, according to government data released on Thursday.
- An updated experimental form of AbbVie Inc's Humira arthritis drug has clear advantages over the original that could help the company confront looming cheaper biosimilar forms of the blockbuster medication, Chief Executive Richard Gonzalez said in an interview.
MONROVIA - Liberia's last Ebola patient left hospital on Thursday to cheers of delight from friends and family, a year after the West African country reported its first case.
- An injection for "double chin" reduction developed by Kythera Biopharmaceuticals Inc cleared the first hurdle toward approval as U.S. Food and Drug Administration staff concluded the drug's benefits outweighed its risks.
MIAMI - A $5 million class-action lawsuit filed this week in Florida accuses hardwood and laminate flooring giant Lumber Liquidators, Inc of selling products laden with cancer-causing chemicals.
(Reuters Health) - Advocates hope that people with colorectal cancer and their caregivers will dress in blue on Friday to raise awareness about the disease, which is the second-leading cancer-related cause of death in the U.S.
LONDON - AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine.
LONDON/GENEVA - Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday.
- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins.